{"disease":{"id":"anticoagulant-adverse-reaction","name":"anticoagulant adverse reaction"},"drugs":{"marketed":[{"drug_id":"andexanet-alfa","indication_name":"Direct acting anticoagulant adverse reaction","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Anxa","generic_name":"ANDEXANET ALFA","company_name":"Portola Pharamceuticals US","drug_phase":"marketed","molecular_target":"","drug_class":"","quality_score":48,"revenue":null,"mechanism":"Anxa works by binding to and neutralizing factor Xa inhibitors, reversing anticoagulation."},{"drug_id":"andexanet","indication_name":"Direct acting anticoagulant adverse reaction","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"Andexanet","company_name":"Portola Pharmaceuticals","drug_phase":"marketed","molecular_target":"","drug_class":"","quality_score":null,"revenue":null,"mechanism":null}],"pipeline":[],"offLabel":[],"totalMarketed":2,"totalPipeline":0},"trials":{"data":[{"nct_id":"NCT06108414","title":"Low-dose Versus Standard-dose Rivaroxaban in Elderly Patients With Atrial Fibrillation","phase":"PHASE4","overall_status":"RECRUITING","enrollment_count":4374,"lead_sponsor_name":"China National Center for Cardiovascular Diseases","has_results":false},{"nct_id":"NCT05332158","title":"Medicines Gaps Study","phase":"NA","overall_status":"UNKNOWN","enrollment_count":3000,"lead_sponsor_name":"The Leeds Teaching Hospitals NHS Trust","has_results":false},{"nct_id":"NCT06187311","title":"Clinical Trial to Evaluate Efficacy and Safety of Rivaroxaban 15mg and 20mg in Patients With Non-valvular Atrial Fibrillation","phase":"PHASE4","overall_status":"RECRUITING","enrollment_count":940,"lead_sponsor_name":"Korea University Anam Hospital","has_results":false},{"nct_id":"NCT04056143","title":"Precision Medicine Platform for Novel Oral Anticoagulants","phase":"","overall_status":"UNKNOWN","enrollment_count":500,"lead_sponsor_name":"Kaohsiung Medical University","has_results":false},{"nct_id":"NCT03297281","title":"Stop or Ongoing Oral Anticoagulation in Patients Undergoing Pvp (SOAP)","phase":"NA","overall_status":"RECRUITING","enrollment_count":389,"lead_sponsor_name":"Clinique Pasteur","has_results":false},{"nct_id":"NCT05292846","title":"Uninterrupted Direct-acting Oral Anticoagulation in Patients Undergoing Transradial Percutaneous Coronary Procedures","phase":"PHASE4","overall_status":"UNKNOWN","enrollment_count":200,"lead_sponsor_name":"Hospital Universitario La Fe","has_results":false},{"nct_id":"NCT04556188","title":"The Clinical Influence of Developing a Sustainable Cardiac Surgery Service to Reduce the Burden of Rheumatic Heart Disease in Sub-Saharan Africa","phase":"","overall_status":"RECRUITING","enrollment_count":200,"lead_sponsor_name":"Helse Nord-Trøndelag HF","has_results":false},{"nct_id":"NCT03926156","title":"RIvoraxaban in Mitral Stenosis","phase":"PHASE3","overall_status":"TERMINATED","enrollment_count":40,"lead_sponsor_name":"Rajaie Cardiovascular Medical and Research Center","has_results":false},{"nct_id":"NCT06079021","title":"COOLEY- Study: aCute On chrOnic Liver failurE Using the cYtosorb Device","phase":"NA","overall_status":"RECRUITING","enrollment_count":20,"lead_sponsor_name":"University Hospital, Antwerp","has_results":false}],"total":9},"guidelines":[],"source":"Drug Landscape verified database"}